Serum β2-Microglobulin in Hemodialyzed Patients
Serum β2-Microglobulin in Hemodialyzed Patients
复制标题
血液透析患者血清 β2-微球蛋白
DOI：
--
复制
发表时间：
1978
期刊：
影响因子：
--
通讯作者：
J. Traeger
中科院分区：
文献类型：
--
作者：
C. Vincent;J. Revillard;M. Galland;J. Traeger
采用放射免疫法测定63例维持性血液透析患者血β2-微球蛋白（β2-M）浓度。血清水平范围为12.5至92 µg/ml，在6个月内连续测量时保持稳定。β2-M的排泄是通过尿液流失（高达150 mg/天）实现的，在较小程度上是通过丙烯聚腈透析膜超滤实现的，而不是通过玻璃纸透析膜。近端肾小管细胞是β2-M催化的主要部位，无肾患者β2-M水平稳定表明尿毒症患者β2-M产生缺陷。血清β2-M水平与透析前尿素、肌酐、红细胞压积及中分子物质无关。体外实验不支持纯化β2-M的可能毒性，但不排除其他低分子量蛋白对尿毒症毒性的贡献。
β2-Microglobulin (β2-M) concentrations were measured by radioimmunoassay in 63 patients treated with maintenance hemodialysis. Serum levels ranged from 12.5 to 92 µg/ml and were found stable upon sequential measurements over a 6-month period. Excretion of β2-M was achieved through urinary loss (up to 150 mg/day) and to a lesser extend by ultrafiltration across acrylopolynitrile but not cellophane dialysis membranes. Proximal tubular cells being the major site of β2-M catabolism, stable levels in anephric patients indicated a defective production of β2-M in uremic patients. Serum β2-M levels were not correlated with predialysis urea, creatinine, hematocrit or middle molecule material. In vitro experiments do not support a possible toxicity of purified β2-M but do not rule out the contribution of other low molecular weight proteins to uremic toxicity.